Dr. Chulhee Choi is the founder and CEO of ILIAS Biologics, a clinical-stage biotech company leading innovation in exosome-based therapeutics. Prior to founding ILIAS, he was a professor of bio and brain engineering at KAIST, where he led groundbreaking research in molecular imaging and therapeutic delivery systems. He spearheaded the development of EXPLOR®, a proprietary platform that enables the active loading of high-molecular-weight therapeutic proteins into exosomes. Under Dr. Choi’s leadership, ILIAS has advanced its lead candidate, ILB-202, through a successful first-in-human Phase 1 clinical trial in 2023, marking a significant milestone in the development of macrophage-targeted anti-inflammatory therapies. He continues to drive the company’s scientific and strategic direction, building a diverse pipeline targeting inflammatory, CNS, renal, and hepatic diseases. Dr. Choi, a founding member of the Extracellular Vesicles Industry Association (EVIA) in Korea, currently serves as its chairman, fostering cross-sector collaboration and regulatory dialogue in the growing field of exosome therapeutics. With a vision that blends deep scientific insight and translational strategy, he is committed to redefining targeted drug delivery and unlocking the full therapeutic potential of engineered exosomes.